CYTKEarnings•globenewswire•
Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update
Sentiment:Negative (30)
Summary
Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China; Late-Cycle Meeting with U.S. FDA Scheduled for September Ahead of December 26, 2025 PDUFA Date
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 7, 2025 by globenewswire